Kevin Tan compensation by year
Solid Biosciences Summary Compensation Table · the one fiscal year held| Component | FY2023 |
|---|---|
| Salary | $416,146 |
| Bonus | $170,000 |
| Stock awards | $270,000 |
| Option awards | $478,279 |
| Non-equity incentive | $0 |
| Pension and deferred compensation | $0 |
| All other | $11,880 |
| Total | $1,346,305 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Solid Biosciences Inc. DEF 14A filed April 26, 2024, accession 0001193125-24-118079, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Solid Biosciences Inc. filed document, accession 0001193125-24-118079. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2024.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 45,000 | $276,300 | — |
| Option | 90,000 | — | $6.00 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Solid Biosciences Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
24 Form 4 lines since the FY2023 proxy (filed April 26, 2024)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-02-18 | Sale | 10b5-1 | 5,404 | $5.82 | 99,422 |
| 2026-02-13 | Exercise or conversion derivative | 10b5-1 | 10,625 | $0.00 | 21,250 |
| 2026-02-13 | Exercise or conversion | 10b5-1 | 10,625 | — | 104,826 |
| 2026-02-04 | Sale | 10b5-1 | 14,783 | $6.44 | 94,201 |
| 2026-02-02 | Sale | 10b5-1 | 26,837 | $6.44 | 108,984 |
| 2026-01-31 | Exercise or conversion derivative | 10b5-1 | 33,075 | $0.00 | 99,225 |
| 2026-01-31 | Exercise or conversion | 10b5-1 | 33,075 | — | 135,821 |
| 2026-01-29 | Grant or award derivative | 10b5-1 | 93,500 | $0.00 | 93,500 |
The 8 most recent of 24 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Solid Biosciences’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Carl Morris | Former Chief Scientific Officer, Neuromuscular (8) | $1,559,449 |
| Kevin Tan · this page | Chief Financial Officer | $1,346,305 |
| Alexander Cumbo | President and Chief Executive Officer | $918,630 |
| David Tyronne Howton | Chief Operating Officer, General Counsel and Secretary | $648,880 |
The full Solid Biosciences compensation record
free company briefThis page is one person within Solid Biosciences's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Solid Biosciences's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.